To help neurologists, clinicians and families understand the current evidence for a new gene therapy for Duchenne muscular ...

The purpose of this report is to re-evaluate such a therapeutic program in muscular dystrophy when the drugs are used singly, in combination and with or without exercise. Objective serial ...

His previous roles at Zafgen, Inc., Biogen, Wyeth Biotech, Pfizer Inc., and Genetics Institute ... its Phase 2 CONNECT2-EDO51 study for Duchenne muscular dystrophy (DMD) to focus on data from ...

The committee was also scheduled to vote on including Duchenne muscular dystrophy. On April 17 ... a professor for genetics and metabolism in the pediatrics department at the University of ...

In addition, we expect to share early clinical results later this year from both BMN 351 for Duchenne Muscular Dystrophy and BMN ... American College of Medical Genetics and Genomics meeting ...

His previous roles at Zafgen, Inc., Biogen, Wyeth Biotech, Pfizer Inc., and Genetics Institute involved significant ... PepGen has temporarily paused its Phase 2 CONNECT2-EDO51 study for Duchenne ...

Scientists present current evidence for a new gene therapy for Duchenne muscular dystrophy called delandistrogene moxeparvovec. AAN Evidence in Focus articles highlight the strength of the current ...

To help neurologists, clinicians and families understand the current evidence for a new gene therapy for Duchenne muscular ...